Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Candel Therapeutics, Inc.NASDAQ: CADL

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2022
-15035.2%
Year-over-year change
+13864.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How CADL compares with its peers on the latest reported figures

CADL Competitors Peer median
Net Margin for CADL and competitors
Company Period LTM level YoY 3-year change
PBYIPuma Biotechnology, Inc.LTM Mar 202610.7% -5.6 pp+13.6 pp
IPSCCentury Therapeutics, Inc.FY2025-8.8% +1912.1 pp+2509.6 pp
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-58.2% +100.6 pp—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-112.0% +645.5 pp—
GNLXGenelux CorporationLTM Mar 2026-397225.0% —-401765.5 pp
CADLCandel Therapeutics, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
IMMXImmix Biopharma, Inc.FY2025— ——
NBPNovaBridge BiosciencesFY2025— ——
Peer median (excluding CADL) -51.5%+100.6 pp+21.8 pp

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue125K125K000
Cost of Revenue00000
Gross Profit125K125K000
Gross Margin100.0%100.0%———
Research & Development15.18M20.79M24.51M19.31M30.5M
Selling, General & Admin10.67M14.06M13.89M14.06M17.77M
Operating Expenses24.78M34.8M38.39M33.37M48.27M
Depreciation & Amortization232K778K960K990K845K
EBITDA(24.42M)(16.31M)(34.38M)(52.1M)(35.22M)
EBITDA Margin-19534.4%-13046.4%———
Operating Income(24.65M)(34.67M)(38.39M)(33.37M)(48.27M)
Operating Margin-19720.0%-27739.2%———
Interest Income01.22M2.08M1.09M3.92M
Interest Expense53K1.71M2.6M2.09M2.12M
Other Income / Expenses(10.4M)15.93M452K(21.81M)10.08M
Income Before Tax(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Pre-Tax Margin-28899.2%-15035.2%———
Income Tax Expense00000
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Net Margin-28899.2%-15035.2%———
EPS (Basic)(1.26)(0.10)(1.31)(1.74)(0.72)
EPS (Diluted)(1.26)(0.10)(1.31)(1.74)(0.72)
Weighted Avg Shares28.69M28.82M28.94M31.68M52.96M
Weighted Avg Shares (Diluted)28.69M28.82M28.94M31.68M52.96M

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.